Clinical trials: MS (Multiple Sclerosis)
Relapsing-Remitting Multiple Sclerosis (RRMS)
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of…
- Trial name
- EMPhASIS (NCT03846219)
- Testing
- IMU-838 (30 mg/day), IMU-838 (45 mg/day), IMU-838 (10 mg/day)
- Where
- 38 sites in Bulgaria, Poland and 2 more
- Volunteers
- 210 people
- Sponsor
- Immunic AG
Multiple Sclerosis
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S.
- Trial name
- ABC's of MS (NCT03808545)
- Testing
- Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
The primary objective of the study was to assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation included the following major components: An assessment of safety and immunogenicity of extended…
- Trial name
- SELECTION (NCT00870740)
- Testing
- BIIB019 (Daclizumab High Yield Process)
- Where
- 58 sites in Czechia, Germany and 6 more
- Volunteers
- 517 people
- Sponsor
- Biogen
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Fatigue
Ketamine for Treatment of MS Fatigue
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system and, after trauma, is the most common cause of disability in young adults, affecting more than 400,000 individuals…
- Trial name
- NCT03500289
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Background: Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These lesions can lead to slow worsening of MS symptoms.
- Trial name
- NCT04742400
- Testing
- tolebrutinib 60mg, tolebrutinib 120mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
- Trial name
- NCT01023074
- Testing
- Auditory training, MS: Control Activity
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
A Study to Test the Use of Duloxetine for Pain in MS
Many patients with Multiple Sclerosis experience pain that is caused by the effects of MS on the nervous system. The purpose of this study is to see if an investigational drug (Duloxetine) will reduce pain in subjects with MS.
- Trial name
- NCT00457730
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse.
- Trial name
- NCT03752307
- Testing
- Isoxsuprine Hydrochloride, Corticosteroid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of New Mexico
Multiple Sclerosis
Cognitive-behavior Therapy for MS-Related Chronic Pain
The purpose of this study is to evaluate the efficacy of a brief psychological intervention, cognitive-behavior therapy, for the management of persistent pain associated with Multiple Sclerosis.
- Trial name
- NCT00323271
- Testing
- Cognitive-behavior therapy, Interventional
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- US Department of Veterans Affairs
Multiple Sclerosis
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT02634307
- Testing
- ALKS 8700
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 1,057 people
- Sponsor
- Biogen
Multiple Sclerosis
Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS
In an individual with MS the central nervous system (CNS) is over-protective and causes the threshold for stretch reflex and muscle tightness to be set lower than normal.
- Trial name
- NCT04942938
- Testing
- Neubie
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- CommonSpirit Health
Multiple Sclerosis
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS)…
- Trial name
- NCT03369665
- Testing
- Mavenclad®
- Where
- 92 sites in Austria, Belgium and 16 more
- Volunteers
- 485 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
MS Spinal Mobilisation Study
The objective of the study is to measure the effect of a spinal mobilisation intervention on para-spinal muscle tissue quality, functional balance measures, pain and fatigue in people with multiple sclerosis.
- Trial name
- NCT05090709
- Testing
- Spinal Mobilisation Intervention, General Massage
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Edinburgh Napier University
Multiple Sclerosis
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body.
- Trial name
- STAYCIS (NCT00094172)
- Testing
- Atorvastatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Fatigue
Cubii for Exercise in People With MS
The goals of this observational study are to evaluate (1) the feasibility, usability, and satisfaction with the Cubii elliptical and (2) the preliminary efficacy of the Cubii elliptical for increasing activity (primary outcome)…
- Conditions
- Multiple Sclerosis, Fatigue, Activity, Motor, Quality of Life
- Trial name
- Cubii (NCT05826431)
- Testing
- Cubii elliptical
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Washington